$UNCY shareholders: Company CEO Shalabh Gupta told them in June 2025 they had a ready backup vendor (good inspection history + already made OLC batches) as a path to fix the manufacturing CRL. They went all-in on the original troubled vendor anyway for the resubmission. Today’s 2nd CRL on the identical issue. Execution choice or something worse? $ARDX CEO Raab SHOULD look to buy these clowns and FIRE current c-suite. This is a fire sale any and all current UNCY shareholders need BEFORE UNCY does a capital raise. Gupta like many Biopharm CEOs has an execution deficit. And at this point I would guess his wife has to call the dog in. @ardelyx
View on X ↗